<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: <z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> is an important chemotherapeutic agent used to reduce hepatic colorectal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, resulting in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> reduction and permitting surgical resection </plain></SENT>
<SENT sid="1" pm="."><plain>This treatment has significant side effects, as <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> can induce <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">sinusoidal obstruction syndrome</z:e> (SOS) in the non-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-bearing liver, resulting in increased morbidity </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that SOS might impede hepatic perfusion, thereby interfering with the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> environment and attenuate the response to the chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: From the prospective database of the Maastricht University Medical Centre we collected 50 patients with hepatic colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received neo-adjuvant <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> followed by partial hepatectomy </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">Metastases</z:e> and non-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-bearing liver were studied histopathologically </plain></SENT>
<SENT sid="6" pm="."><plain>Thirty-two of 50 (64%) patients showed SOS lesions, classified as mild (26%) and moderate-severe (38%) </plain></SENT>
<SENT sid="7" pm="."><plain>The response to treatment, as expressed in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> regression grade (TRG), was grade 1 (10%); grade 2 (14%); grade 3 (28%); grade 4 (32%) and grade 5 (16%) </plain></SENT>
<SENT sid="8" pm="."><plain>Statistical analysis showed that a higher grade of SOS was associated with a higher grade of TRG (P = 0.016) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Developing SOS is associated with a lower <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> response to neo-adjuvant <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> treatment </plain></SENT>
<SENT sid="10" pm="."><plain>Hepatic hypoperfusion due to <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">sinusoidal obstruction syndrome</z:e> might induce hepatic <z:mp ids='MP_0005039'>hypoxia</z:mp>, diminishing the response to chemotherapy </plain></SENT>
</text></document>